Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Italy Fines Apple €98.6 Million Over App Store Dominance 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
REDWOOD CITY, Calif., July 26, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the second quarter of 2017 after the close of trading on Tuesday, August 8, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (844) 776-7820 for domestic callers or (661) 378-9536 for international callers and referencing Conference ID: 58223692. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com.
A replay of the call will be available beginning August 8, 2017 at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on August 9, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 58223692. The webcast will also be available on Avinger's website for one year following the completion of the call.
About Avinger, Inc.
Founded in 2007, Avinger, Inc. is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral arterial disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through their Lumivascular platform which currently consists of the Lightbox imaging console, the Ocelot family of catheters designed for chronic total occlusions (CTOs), and Pantheris designed for atherectomy. Avinger is based in Redwood City, CA. For more information, please visit www.avinger.com.
Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
